Evidence map›Paper›PMID 42741627›Full record

ArticleACS medicinal chemistry letters2026

Discovery of High-Affinity Peptide Ligands Targeting the SPIN1 Tudor 3 Domain Via a Minimalist Pruning Strategy.

Alessandra Feoli, Giulio Esposito, Manuela Grimaldi, Monica Viviano, Ida Pacilio, Josef Krátký, Anna Maria D'Ursi, Ciro Milite, Haitao Li, Mark T Bedford and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandra Feoli‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0002-8960-7858
Giulio Esposito‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.
Manuela Grimaldi‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0001-7354-8008
Monica Viviano‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0003-1118-790X
Ida Pacilio‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0009-0004-0596-1107
Josef KrátkýDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
Anna Maria D'Ursi‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0001-6814-8472
Ciro Milite‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0003-1000-1376
Haitao LiState Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, Beijing Frontier Research Center for Biological Structure, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing, 100084, China.ORCID https://orcid.org/0000-0001-6741-293X
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Sabrina Castellano‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0002-7449-3704
Gianluca Sbardella‡Department of Pharmacy and ∫PhD Program in Drug Discovery and Development, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0003-0748-1145

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spindlin1 (SPIN1) is an epigenetic reader involved in oncology, whose third Tudor domain remains largely underexplored. Here, we applied a minimalist pruning strategy to the 26-mer peptide DOCpep3 to identify the core pharmacophore for SPIN1 Tudor 3 domain binding. This yielded truncated linear peptide analogues (e.g.,

Indexed as

epigeneticspeptide ligandsprotein conformational changesSPIN1Spindlin1SPINDOCTudor domain

Identifiers

PMID42741627
PMCPMC13573250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.